SUTRO BIOPHARMA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.85 USD | -1.28% |
|
+2.39% | -10.26% |
| Jun. 03 | Vgxi Inc. Announces Strategic Partnership with Sutro Biopharma Inc. to Support Growing Clinical Pipeline | CI |
| May. 13 | Sutro Biopharma Q1 Loss Widens, Revenue Rises | MT |
Financials (USD)
| Sales 2024 * | 56.24M | Sales 2025 * | 62.17M | Capitalization | 315M |
|---|---|---|---|---|---|
| Net income 2024 * | -237M | Net income 2025 * | -271M | EV / Sales 2024 * | 1.55 x |
| Net cash position 2024 * | 228M | Net cash position 2025 * | 376M | EV / Sales 2025 * | -0.98 x |
| P/E ratio 2024 * |
-1.12
x | P/E ratio 2025 * |
-1.19
x | Employees | 300 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.99% |
More Fundamentals
* Assessed data
More news
Latest transcript on Sutro Biopharma, Inc.
More recommendations
More press releases
More news
| 1 day | -1.28% | ||
| 1 week | +2.39% | ||
| Current month | -8.88% | ||
| 1 month | -8.98% | ||
| 3 months | -15.57% | ||
| 6 months | -2.04% | ||
| Current year | -10.26% |
1 week
3.61
4.02
1 month
3.615.09
Current year
3.206.13
1 year
2.016.13
3 years
2.0123.70
5 years
2.0128.30
10 years
2.0128.30
| Managers | Title | Age | Since |
|---|---|---|---|
William Newell
CEO | Chief Executive Officer | 66 | 09-01-13 |
Jane Chung
PSD | President | 53 | 21-08-08 |
Edward Albini
DFI | Director of Finance/CFO | 66 | 13-01-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Connie Matsui
CHM | Chairman | 70 | 19-06-23 |
James Panek
BRD | Director/Board Member | 71 | 20-01-06 |
Daniel Petree
BRD | Director/Board Member | 68 | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.04% | 0 M€ | 0.00% | - | |
| 0.02% | 0 M€ | 0.00% | - | |
| 0.01% | 9 M€ | +10.39% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-13 | 3.85 | -1.28% | 333,305 |
| 24-06-12 | 3.9 | +2.09% | 438,603 |
| 24-06-11 | 3.82 | -0.78% | 349,671 |
| 24-06-10 | 3.85 | +3.77% | 605,802 |
| 24-06-07 | 3.71 | -1.33% | 419,765 |
Delayed Quote Nasdaq, June 13, 2024 at 04:00 pm EDT
More quotes
Sutro Biopharma, Inc. is a clinical-stage oncology company. The Company is engaged in developing site-specific and novel-format antibody drug conjugates (ADCs) enabled by its integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. The Companyâs advanced product candidate is STRO-002 (luveltamab tazevibulin, or luvelta), an ADC directed against folate receptor-alpha (FolRa), for patients with FolRa-expressing cancers, including ovarian cancer. In addition, it uses luvelta to treat pediatric patients with relapsed/refractory CBFA2T3-GLIS2 and acute myeloid leukemia. It also has two preclinical product candidates, STRO-003 and STRO-004. These product candidates are single homogeneous ADCs directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1), and tissue factor (TF), each of which is being developed for the treatment of solid tumors.
Calendar
2024-08-07
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
3.85
USD
Average target price
12.6
USD
Spread / Average Target
+227.27%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -10.26% | 315M | |
| +17.73% | 124B | |
| +16.88% | 111B | |
| -9.04% | 23.17B | |
| +5.50% | 22.94B | |
| -38.15% | 17.42B | |
| -7.75% | 17.42B | |
| -14.62% | 16.9B | |
| +3.42% | 13.71B | |
| +29.63% | 11.82B |
- Stock Market
- Equities
- STRO Stock
